<DOC>
	<DOCNO>NCT01826266</DOCNO>
	<brief_summary>PER977 monotherapy co-administration follow 60 mg edoxaban acceptable safety tolerability profile impact pro-coagulant biomarkers . A dose PER977 reverse effect edoxaban pharmacodynamic ( PD ) biomarkers ( point care prothrombin time [ PoC-PT ] ) , and/or secondary biomarkers ( thromboelastography reaction time [ TEG-R ] ) identify .</brief_summary>
	<brief_title>Effects Double-Blind , Single Dose PER977 Administered Alone , Following Single Dose Edoxaban</brief_title>
	<detailed_description>Normal subject dose PER977 placebo alone 1 week later , give single dose edoxaban follow 3 hour single IV dose PER977 . The purpose show safety tolerability PER977 alone combine NOAC ( edoxaban ) . The study also provide insight dos may require reverse steady state edoxaban .</detailed_description>
	<mesh_term>Edoxaban</mesh_term>
	<criteria>1 . Adults age 18 45 year , inclusive 2 . Laboratory value ( chemistry , complete blood count coagulation assessment ) urinalysis perform screen 21 day prior administration study treatment within normal limit . 3 . No clinically significant finding 12lead electrocardiogram ( ECG ) perform screen . 4 . Body mass index ( BMI ) 18 ≤32 kg/m2 , inclusive 5 . Male subject agree use appropriate contraception ( i.e. , double barrier contraception latex condom spermicide female partner childbearing potential ( nonmenopausal female one following : ) hysterectomy ( without oophorectomy ) , b ) bilateral oophorectomy without hysterectomy , c ) medically document ovarian failure ) use diaphragm cervical cap single barrier contraception female partner use intrauterine device hormonal contraceptive sterilize ; barrier require female partner hysterectomy ) engage sexual activity course study . Moreover , male subject donate sperm attempt impregnate partner course study period 12 week follow discharge study . 6 . Female subject nonchildbearing potential ( menopausal female 3 definition menopause ) agree use two form nonhormonal contraceptive ( e.g . barrier method [ condom diaphragm ] ) intrauterine device duration study 30 day follow completion study . Women consider postmenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g . age appropriate , history vasomotor symptom ) surgical bilateral oophorectomy ( without hysterectomy ) tubal ligation least six week ago . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider child bear potential . 7 . Nonsmokers nonusers nicotine contain product within 3 month dose ( occasional use tobacco product within 30 day dose consider casebycase basis ) 8 . Subjects must understand agree comply requirement study must willing sign inform consent form indicate voluntary consent participate study prior initiation screen study related activity . 1 . History current evidence clinically significant cardiac , hepatic , renal , pulmonary , endocrine , neurologic , infectious , gastrointestinal , hematologic , oncologic disease determine screen history , physical examination , laboratory test result 12lead ECG . History current evidence liver function test great upper limit normal . History current evidence QTc Fridericia ( QTcF ) great normal ( 430±10 msec male 450±10 msec female ; average three measurement ) . 2 . History unexplained syncope 3 . Use drug substance know strong inhibitor strong inducer CYP3A4/5 transporter pglycoprotein within 28 day prior first dose 4 . History major bleeding , trauma , surgical procedure type , vaginal delivery within six month prior screen 5 . History peptic ulcer , gastrointestinal bleeding ( include hematemesis , melena , rectal bleeding ) bleeding hemorrhoid within six month prior screen 6 . History minor bleeding episode epistaxis , rectal hemorrhoidal bleeding ( spots blood toilet paper ) gingival bleed within 3 month prior screen 7 . Personal family history clot disorder abnormality , excessive bleeding , thrombovascular disease hematologic disorder involve platelet clot abnormality condition require treatment transfusion , anticoagulant platelet inhibitor 8 . Females history dysfunctional uterine bleeding , include history menorrhagia ( heavy menstrual bleeding ) , metrorrhagia polymenorrhea current use hormonal contraceptive . 9 . Pregnant breastfeed 10 . Male subject history hormone therapy within 3 month prior screen 11 . Administration blood product anticoagulant within 3 month prior study entry nonsteroidal antiinflammatory drug cyclooxygenase inhibitor within 2 week prior screen 12 . Taking type chronic medication within 4 week prior study entry 13 . Positive serologic test human immunodeficiency virus ( HIV ) , Hepatitis C virus ( HCV ) , Hepatitis B surface antigen ( HBsa ) 14 . Use following medication 4 week prior study entry : rifampin , dronedarone , ketoconazole , verapamil , amiodarone , quinidine , clopidogrel , oral anticoagulant , agent know interact edoxaban 15 . Donation blood blood product within 56 day prior enrollment 16 . Participation study investigational compound device within 30 day prior sign inform consent 17 . Active drug , alcohol nicotine use dependence condition , opinion Investigator , would interfere adherence study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>PER977</keyword>
	<keyword>Activated partial thromboplastin time</keyword>
	<keyword>Assessment</keyword>
	<keyword>D-dimer</keyword>
	<keyword>Enrollment</keyword>
	<keyword>Investigational drug</keyword>
	<keyword>Investigational treatment</keyword>
	<keyword>Period</keyword>
	<keyword>Premature subject withdrawal</keyword>
	<keyword>Prothrombin time</keyword>
	<keyword>Randomization number</keyword>
	<keyword>Study discontinuation</keyword>
	<keyword>Study drug</keyword>
	<keyword>Subject number</keyword>
	<keyword>Study treatment</keyword>
	<keyword>Thromboelastography-reaction time</keyword>
</DOC>